Guatemala’s health committee rejects a medical cannabis bill

Guatemala’s congressional Health Committee opposed a bill for medicinal, therapeutic and scientific cannabis production and supply in 2017. Prensa Libre reported in October that fourteen of the committee’s eighteen members had signed an adverse opinion, leaving the proposed medical system without its support.

Reformers had already tried broader adult access

The 2016 adult cannabis bill proposed private adult consumption, five home plants and licensed commercial supply. It would have created cannabis exceptions to criminal offences governing possession, cultivation and distribution.

That bill received committee opposition. Its proposed 10% sales tax, quality controls and household growing permissions remained part of the political discussion.

The later effort placed medical access at the centre of the proposal, continuing Álvaro Velásquez’s push for a change in how Guatemala regulated cannabis.

A renewed proposal focused on pharmacies and doctors

Prensa Libre had described Velásquez’s renewed medical proposal in December 2016. It envisaged pharmacy supply and medical or psychiatric supervision for medicinal and therapeutic use.

It would also permit scientific research and create a regulator to oversee activities including growing, production, storage and international trade. Those proposed duties connected patients’ access to the organisation of a lawful supply chain.

For doctors and pharmacists, the proposal offered roles in authorising and supplying treatment within a dedicated cannabis system.

Committee members questioned regulatory capacity

The Health Committee cited the state’s constitutional duties to protect people and control products affecting health. Member Marvin Orellana told Prensa Libre that medicine-testing laboratories needed modernising before the proposed system could be considered.

The opposition therefore addressed Guatemala’s capacity to supervise a medical market as well as the case for changing cannabis policy. Fourteen signatures gave the proposal a clear adverse committee opinion.

Existing drug offences still governed cannabis handling

The 1992 drug law prescribed four months to two years in prison plus a fine for personal possession, five to twenty years for unauthorised cultivation and twelve to twenty years for trafficking.

Its lawful-use rule separately allowed strictly necessary quantities for medical treatment, research, analysis and medicine manufacture by authorised people, with prescriptions required for sales to private customers.

The committee setback left the proposed cannabis-specific production and supply system facing political opposition within that wider system of drug controls in Guatemala.^[1][2][3][4]